Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
156studies shown
Showing 1-12 of 156
Drug study icon
RecruitingNCT05511363

KarXT for Schizophrenia

This study is recruiting in the United States, in France, in the United Kingdom, .... It is testing KarXT for Schizophrenia.

In France
SchizophreniaDrugA study involving a medication or substance.From 55 Years to 90 Years
Countries
United States, France, United Kingdom, ...
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
Drug study icon
RecruitingNCT06887192

ML-007C-MA for Schizophrenia

This study is recruiting in the United States, in France, in Canada, .... It is testing ML-007C-MA for Schizophrenia.

In France
SchizophreniaDrugFrom 55 Years to 90 Years
Countries
United States, France, Canada, ...
Sponsor
MapLight Therapeutics
Condition
Schizophrenia
Drug study icon
RecruitingNCT06929273

KarXT for manic episodes in bipolarity type I

This study is recruiting in the United States, in Australia, in France, .... It is testing KarXT for manic episodes in bipolarity type I.

In France
BipolarityDrugFrom 18 Years to 65 Years
Countries
United States, Australia, France, ...
Sponsor
Bristol-Myers Squibb
Condition
Bipolarity
Drug study icon
RecruitingNCT06585787

KarXT for Schizophrenia

This study is recruiting in the United States, in France, in Belgium, .... It is testing KarXT for Schizophrenia.

In France
SchizophreniaDrugFrom 55 Years to 90 Years
Countries
United States, France, Belgium, ...
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
Drug study icon
RecruitingNCT07140913

KarXT for manic episodes in bipolarity type I

This study is recruiting in the United States, in France, in Argentina, .... It is testing KarXT for manic episodes in bipolarity type I, including participants taking lithium, valproate, or lamotrigine.

In France
BipolarityDrugFrom 18 Years to 65 Years
Countries
United States, France, Argentina, ...
Sponsor
Bristol-Myers Squibb
Condition
Bipolarity
Drug study icon
RecruitingNCT07424404

KarXT and KarX-EC for schizophrenia

This study is recruiting in the United States, in France, in Canada, .... It is testing KarXT and KarX-EC for schizophrenia.

In France
SchizophreniaDrugFrom 5 Years to 17 Years
Countries
United States, France, Canada, ...
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
Drug study icon
RecruitingNCT06159673

ACP-204 in Adults With Alzheimer's Disease Psychosis

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Brazil, Bulgaria, Chile, Czech Republic, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan, and the United States.

In France
SchizophreniaDrugFrom 55 Years to 95 Years
Countries
United States, France, Brazil, ...
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
Other study type icon
RecruitingNCT07540429

ADOLESCENTS IMAGING USING fMRI: Feasibility Study

This study is recruiting. It focuses on ADHD and currently lists participation information in France.

In France
ADHDDiagnostic TestA study that looks at how to detect, measure, or better understand a condition.From 12 Years to 17 Years
Countries
France
Sponsor
Etablissement Public de la Sante Mentale de la Somme
Condition
ADHD
Device study icon
RecruitingNCT07642882

Analgesic Efficacy of Multisite rTMS in Fibromyalgia Patients

This study is recruiting. It focuses on depression and currently lists participation information in France.

In France
DepressionDeviceA study involving a tool, app, wearable, test, or medical device.From 18 Years to 80 Years
Countries
France
Sponsor
Hospital Ambroise Paré Paris
Condition
Depression